Table 1.

Financing modalities characteristics

Financing modalities	Nomenclature reimbursment codes	Reference laboratories (RLs)	Conventions with foreign laboratories
Type of medical analyses	Analyses of clinical pathology
Analyses’ availability	Available in Belgium		Not available in Belgium
Annual volume	High	Moderate to low	Low
Laboratories who can benefit from the financing	All Belgian laboratories of clinical pathology	Only Belgian laboratories of clinical pathology recognized as RLs	Specific foreign laboratories of clinical pathology
Laboratories’ selection procedure	None	Belgian call for application By Sciensano Every 5 years	By the RDWG of the BCCP and Sciensano Every year
Components of the financing	Performance of the analysis	Analytical costs Accreditation Quality controls Specific administrative costs	Analytical costs Shipment costs
Financing source	INAMI-RIZIV (through a budget envelop specifically dedicated to the Action 1 of the Belgian plan for rare diseases)
Follow-up of laboratories’ activities and quality of the analyses	By the RDWG of the BCCP and Sciensano
Annual evaluation of the necessary budget	By Sciensano and the INAMI-RIZIV Insurance Committee

BCCP Belgian Commission on Clinical Pathology, INAMI-RIZIV National Institute for Health and Disability Insurance, RDWG Rare Diseases Working Group, RLs reference laboratories